Andalibi Fatemeh, Bostanghadiri Narjess, Amirmozafari Nour, Irajian Gholamreza, Mirkalantari Shiva
Microbial Biotechnology Research Center, Iran University of Medical Sciences, Tehran, Iran.
Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
J Clin Tuberc Other Mycobact Dis. 2024 Jul 6;36:100463. doi: 10.1016/j.jctube.2024.100463. eCollection 2024 Aug.
() is a non-tuberculosis bacterium with a highly prevalent that is transferred by aerosols from water and soil resources to the respiratory system. is one of the main species responsible for NTM pulmonary disease.
Web of Science, Scopus, and PubMed databases were systematically explored. Relevant articles from 1971 to November 2023 were reviewed. "The inclusion criteria" included patients with infection, treatment follow-up, and treatment outcomes. "The exclusion criteria" were clinical samples from animals, environmental samples, and other laboratory investigations.
40 studies, including 1201 patients, were obtained through database search. Using the therapeutic regimens used in different studies, the therapy course for patients with infection ranged from 1 week to 118 months. In this study, the antibiotics prescribed in different treatment regimens for pulmonary infection were as follows: Rifampin, Ethambutol, Isoniazid, Clarithromycin, Streptomycin, and Pyrazinamide. Antibiotic combinations of three or four medicines, including rifampin, ethambutol, and isoniazid with or without streptomycin or pyrazinamide had the most therapeutic effect.
The initial treatment involves rifampin, ethambutol, isoniazid, and pyridoxine, per the guidelines from the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA). Understanding the treatment plan and its outcomes is crucial for managing and determining the most effective therapy approach.
（）是一种非结核分枝杆菌，其传播极为普遍，可通过气溶胶从水和土壤资源传播至呼吸系统。它是导致非结核分枝杆菌肺病的主要菌种之一。
系统检索了科学网、Scopus和PubMed数据库。对1971年至2023年11月的相关文章进行了综述。“纳入标准”包括感染患者、治疗随访和治疗结果。“排除标准”为动物的临床样本、环境样本和其他实验室研究。
通过数据库检索获得了40项研究，包括1201名患者。根据不同研究中使用的治疗方案，感染患者的治疗疗程为1周-118个月。在本研究中，不同治疗方案用于肺部感染所开具的抗生素如下：利福平、乙胺丁醇、异烟肼、克拉霉素、链霉素和吡嗪酰胺。包括利福平、乙胺丁醇和异烟肼加或不加链霉素或吡嗪酰胺的三药或四药联合抗生素治疗效果最佳。
根据美国胸科学会（ATS）和美国感染病学会（IDSA）的指南，初始治疗包括使用利福平、乙胺丁醇、异烟肼和吡哆醇。了解治疗方案及其结果对于管理和确定最有效的治疗方法至关重要。
